Vorinostat is a well-characterized histone deacetylase (HDAC) inhibitor approved by the FDA for the treatment of cutaneous T-cell lymphoma (CTCL) [23,24,25]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.